Patents Assigned to Ethypharm
  • Patent number: 6488964
    Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: December 3, 2002
    Assignee: Societe Laboratoires des Products Ethiques - Ethypharm
    Inventors: Etienne Bruna, Edouard Gendrot, Charles Chauveau, Alain-Gilles Demichelis
  • Patent number: 6482437
    Abstract: The present invention relates to a novel oral immediate-release morphine sulfate formulation in the form of microgranules. Each microgranule comprises a neutral support grain coated with a mixture of morphine sulfate and of a binder, such as hydroxypropylmethylcellulose, which represents 10 to 50% by weight of the morphine sulfate/binder mixture. The present invention also relates to a process for the preparation of these microgranules which is carried out entirely in aqueous medium on neutral support grains. The present invention finally relates to the pharmaceutical preparations comprising the microgranules according to the invention.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: November 19, 2002
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
  • Patent number: 6458389
    Abstract: The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: October 1, 2002
    Assignee: Laboratoires Des Produits Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
  • Publication number: 20020098227
    Abstract: The invention concerns a method for making coated granules with masked taste and instant release of the active principle which consists in: first, mixing the constituents of a powder comprising at least the active principle and a granular disintegrating agent; then, granulating the resulting powder, in the presence of a mixture of carriers comprising at least a binding agent capable of binding the particles together to obtain grains; coating the grains formed by spraying a suspension comprising at least a coating agent and a membrane disintegrating agent; finally drying the resulting coated granules.
    Type: Application
    Filed: January 8, 2002
    Publication date: July 25, 2002
    Applicant: Ethypharm
    Inventors: Noureddine Nouri, Jean-Marc Zuccarelli, Etienne Bruna, Charles Chauveau
  • Patent number: 6383516
    Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: May 7, 2002
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gérard Leduc, Pascal Oury, Pascal Suplie
  • Publication number: 20020051749
    Abstract: The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of least 90 weeks, a thereapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used prefereably contain 5-fluorouracile of the tumor, by intratissular injection. The radiothereapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.
    Type: Application
    Filed: November 16, 2001
    Publication date: May 2, 2002
    Applicant: Laboratoires Des Produits Ethiques Ethypharm
    Inventors: Nathalie Faisant, Jean-Pierre Benoit, Philippe Menei
  • Patent number: 6379700
    Abstract: The invention concerns a method for making tablets with active principle sustained-release which consists in: preparing a fluid oil-in-water emulsion; spraying the resulting emulsion on a powder mixture containing at least the active principle; subjecting said treated powder to a compressing step, to obtain tablets.
    Type: Grant
    Filed: December 8, 2000
    Date of Patent: April 30, 2002
    Assignees: Gattefosse S.A., Ethypharm
    Inventors: Joseph Joachim, Pascal Prindirre, Nabil Farah
  • Publication number: 20020012679
    Abstract: A process for manufacturing coated particles of &ggr;-aminobutyric acid analogue, whose lactam content by weight relative to the weight of &ggr;-aminobutyric acid analogue is less than 0.5% is disclosed. The process is characterized in that a coating solution of at least one polymer in an organic solvent is sprayed onto the particles of &ggr;-aminobutyric acid analogue.
    Type: Application
    Filed: February 5, 2001
    Publication date: January 31, 2002
    Applicant: Societe Laboratoires des Produits Ethiques - Ethypharm
    Inventors: Etienne Bruna, Edouard Gendrot, Charles Chauveau, Alain-Gilles Demichelis
  • Patent number: 6228395
    Abstract: Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: May 8, 2001
    Assignee: Laboratories des Produits Ethiques Ethypharm
    Inventors: Patrice DeBregeas, Gérard LeDuc, Pascal Oury, Pascal Suplie
  • Patent number: 6139877
    Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing tiagabine as active principle. The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids. These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the tiagabine contained in the spheroids following a possible compression step.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: October 31, 2000
    Assignee: Laboratoires des Produits Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
  • Patent number: 6077544
    Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing one or more active principles, which the exception of tiagabine.The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids.These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the active principle(s) following a possible compression step.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: June 20, 2000
    Assignee: Laboratoires des Products Ethiques Ethypharm
    Inventors: Patrice Debregeas, Gerard Leduc, Pascal Oury, Pascal Suplie
  • Patent number: 6071539
    Abstract: According to the present invent, effervescent granules having a controllable rate of effervescence are provided. Such granules comprise an acidic agent, an alkaline agent, a hot-melt extrudable binder capable of forming a eutectic mixture with the acidic agent and, optionally, a plasticizer. The effervescent granules are made by a hot-melt extrusion process.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: June 6, 2000
    Assignee: Ethypharm, SA
    Inventors: Joseph R. Robinson, James W. McGinity
  • Patent number: 5549911
    Abstract: The present invention relates to a galenic form of 5-nitroimidazole derivatives which is characterized in that it comprises a combination of microgranules of 5-nitroimidazole derivatives consisting, on the one hand, of gastroresistant microgranules and, on the other hand, of prolonged-release microgranules, the pharmaceutical compositions comprising them and the microgranules as intermediates in the preparation of the form according to the invention.
    Type: Grant
    Filed: January 11, 1995
    Date of Patent: August 27, 1996
    Assignee: Laboratoires Des Produits Ethiques Ethypharm
    Inventors: Gerard Leduc, Patrice Debregeas
  • Patent number: 5385739
    Abstract: The present invention relates to a stable formulation of omeprazole microgranules containing a neutral core consisting of sugar and starch, characterized in that it contains an active layer consisting of a dilution of omeprazole in mannitol in substantially equal amounts. It also relates to a process for producing such formulations.
    Type: Grant
    Filed: June 16, 1993
    Date of Patent: January 31, 1995
    Assignee: Ethypharm
    Inventors: Patrice Debregeas, Gerard Leduc
  • Patent number: 4961890
    Abstract: A process for preparing a controlled release medicine containing fenofibrate in an intermediate layer in the form of cyrstalline microparticles included within pores of an inert matrix prepared by a process involving the sequential steps of dampening said inert core with a solution based on said biner, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying before said solution based on said binder dissolves said fenofibrate microparticles and repeating said three steps in sequence until said intermediate layer is formed.
    Type: Grant
    Filed: October 12, 1988
    Date of Patent: October 9, 1990
    Assignee: Ethypharm
    Inventor: Jean-Francois Boyer
  • Patent number: 4960596
    Abstract: The slow release preparation obtained by the method of the invention reduces the number of times the medicine needs to be taken per day, and also provides lower peaks of concentration in the blood after the medicine has been taken while simultaneously ensuring that the lowest concentration in the blood remains higher over a period of time.
    Type: Grant
    Filed: November 23, 1988
    Date of Patent: October 2, 1990
    Assignee: Ethypharm
    Inventors: Patrice Debregeas, Gerard Leduc, Jean-Francois Boyer
  • Patent number: RE35903
    Abstract: The slow release preparation obtained by the method of the invention reduces the number of times the medicine needs to be taken per day, and also provides lower peaks of concentration in the blood after the medicine has been taken while simultaneously ensuring that the lowest concentration in the blood remains higher over a period of time.
    Type: Grant
    Filed: June 23, 1992
    Date of Patent: September 22, 1998
    Assignee: Ethypharm
    Inventors: Patrice Debregeas, Gerard Leduc, Jean-Francois Boyer